Heart failure & cardiomyopathies
The Role of Cardiac Acoustic Biomarkers in Monitoring Patients with Heart Failure: A Systematic Literature Review
Authors' conclusion
Published literature supported S3 and EMAT as robust CAB measures in HF that may have value in remote clinical monitoring and management of patients with HF.
Study context
- Population
- Patients with heart failure (HF) evaluated with cardiac acoustic biomarkers (CABs)27 publications
- Outcome
- Associations between CABs and HF outcomes
Methodological detailsJoanna Briggs Institute (JBI) critical appraisal, 3074 records screened, 73 full-text articles assessed, Embase and MEDLINE searched, 2013–2023; grey literature January 2021 to May 2023
- JBI critical appraisal
- 3074 records screened, 73 full-text articles assessed
- Embase and MEDLINE searched, 2013–2023; grey literature January 2021 to May 2023
Main finding
As reported in the abstract
CABs reported for monitoring HF
- Publications on S3 characteristics and role in HF detection or outcomes
- 15
- S3 assessment among various groups of patients with HF
- 6
- S3 strength or amplitude with clinical outcomes
- 4
- S3 presence and clinical outcomes
- 5
- Both S3 presence and amplitude with HF clinical outcomes
- 1
- Publications on electromechanical activation time (EMAT) and its derivatives
- 11
- EMAT and HF
- 5
- EMAT and HF clinical outcomes
- 6
Original publication
The Role of Cardiac Acoustic Biomarkers in Monitoring Patients with Heart Failure: A Systematic Literature Review. ESC Heart Fail. Published 18 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →